Get started
Author

Nada A. Ashour

Observed name: Nada A Ashour
ORCID: 0000-0001-6250-7198
Observed ORCID: 0000-0001-6250-7198
OpenAlex ID: A5005937336
Diabetes mellitus: Classification, mediators, and complications; A gate to identify potential targets for the development of new effective treatments
2023 · Samar A. Antar, Nada A. Ashour, et al. · Biomedicine & Pharmacotherapy · 835
Fibrosis: Types, Effects, Markers, Mechanisms for Disease Progression, and Its Relation with Oxidative Stress, Immunity, and Inflammation
2023 · Samar A. Antar, Nada A. Ashour, et al. · International Journal of Molecular Sciences · 415
PDF
Metformin role in Parkinson’s disease: a double-sword effect
2023 · Mohamed Alrouji, Hayder M. Al-kuraishy, et al. · Molecular and Cellular Biochemistry · 105
A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval
2022 · Nada A Ashour, Ayman Abo Elmaaty, et al. · Drug Design Development and Therapy · 55
PDF
Medicinal chemistry perspectives on anticancer drug design based on clinical applications (2015–2025)
2025 · Ahmed A. Al-Karmalawy, Mohamed E. Eissa, et al. · RSC Advances · 42
PDF
The journey of antimalarial drugs against SARS-CoV-2: Review article
2021 · Amany A. Sarhan, Nada A. Ashour, et al. · Informatics in Medicine Unlocked · 35
Exploring drug-induced liver injury: comprehensive insights into mechanisms and management of hepatotoxic agents
2025 · Ahmed K. Saleh, Thanaa A. El-Masry, et al. · Future Journal of Pharmaceutical Sciences · 22
Potential role of tirzepatide towards Covid-19 infection in diabetic patients: a perspective approach
2023 · Gaber El-Saber Batiha, Hayder M. Al-kuraishy, et al. · Inflammopharmacology · 18
PDF
Targeting AMPK with ivabradine attenuates cyclophosphamide-induced hepatotoxicity: Crosstalk with MAPK, JAK1/STAT3, and PI3K/Akt pathways
2025 · Ahmed M. El-Dessouki, Mohamed E. Eissa, et al. · Naunyn-Schmiedeberg s Archives of Pharmacology · 10
Modulation of AMPK/SIRT1 signaling by piribedil attenuates cyclophosphamide-induced nephrotoxicity via PI3K/Akt, MAPKs, and TLR4/NLRP3 pathways with regulation of KIM-1/NGAL
2026 · Ahmed M. El-Dessouki, Tarek A. Yousef, et al. · Naunyn-Schmiedeberg s Archives of Pharmacology · 5
Designing the Next Generation of Antibiotics: Structure, SAR, and Strategy in Medicinal Chemistry (2000–2025)
2026 · Ahmed A. Al‐Karmalawy, Abdullah Al‐Dakhil, et al. · Medicinal Research Reviews · 3
Autism and α7-nicotinic acetylcholine receptors: new pharmacological and herbal interventions
2025 · Nourhan A. Khattab, Aya H. El-Kadem, et al. · Future Journal of Pharmaceutical Sciences · 3
PDF
Buspirone attenuates cyclophosphamide-induced renal dysfunction in association with alterations in miR-205/EGLN2, Nrf2, and PERK/ATF4/CHOP signaling
2026 · Ahmed M. El-Dessouki, Amal Abdullah Alrashidi, et al. · Frontiers in Pharmacology · 1
PDF
Recent advances in COVID-19-induced liver injury: causes, diagnosis, and management
2024 · Samar A. Antar, Nada A. Ashour, et al. · Inflammopharmacology · 1
Author response for "Medicinal chemistry perspectives on anticancer drug design based on clinical applications (2015–2025)"
2025 · Ahmed A. Al-Karmalawy, Mohamed E. Eissa, et al. · Publons reviews and discussion
A novel combination therapy using Dapagliflozin and Cycas media extract in experimentally induced diabetic wounds by targeting novel pathways in wound healing
2024 · Nada A. Ashour, Thanaa A. El-Masry, et al. · International Immunopharmacology
Works count: 16
Citation count: 1,550
H-index: 9
I10-index: 9
Year
Topic
Type